https://www.pharmaradar360.com/article/ukhsa-expands-wastewater-surveillance-to-strengthen-early-warning-system-for-dan-cebf5a4b17395e76PharmaRadar360en2026-09-23T11:00:02.000ZUKHSA expands wastewater surveillance to strengthen ‘early warning system’ for dangerous pathogenshttps://www.pharmaradar360.com/article/aurion-biotech-completes-enrollment-in-pivotal-astra-phase-3-study-advancing-aur-b6711b307932a822PharmaRadar360en2026-09-23T11:00:00.000ZAurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial Dysfunctionhttps://www.pharmaradar360.com/article/jefferies-raises-amgen-stock-price-target-on-drug-trial-success-cc7e529ee5fe6e74PharmaRadar360en2026-09-23T10:21:52.000ZJefferies raises Amgen stock price target on drug trial successhttps://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-christoph-weber-for-board-seat-eb5e783eba6901a0PharmaRadar360en2026-09-23T10:11:38.000ZRoche proposes former Takeda CEO Christoph Weber for board seathttps://www.pharmaradar360.com/article/shanghai-henlius-biotech-inc-and-amberstone-biosciences-inc-enter-collaboration-fc21a4575dc1493dPharmaRadar360en2026-09-23T10:05:54.000ZShanghai Henlius Biotech, Inc. And Amberstone Biosciences, Inc. Enter Collaboration And License Agreement For Two T Cell Engager Productshttps://www.pharmaradar360.com/article/ai-biotech-startup-enveda-doubles-in-value-to-2-billion-wsj-2a17d33df3769840PharmaRadar360en2026-09-23T10:03:47.000ZAI biotech startup Enveda doubles in value to $2 billion - WSJhttps://www.pharmaradar360.com/article/abortion-statistics-user-engagement-plan-65fe5013a86b6246PharmaRadar360en2026-09-23T10:00:04.000ZAbortion statistics user engagement planhttps://www.pharmaradar360.com/article/abortion-statistics-in-england-and-wales-62845a4d19ed888cPharmaRadar360en2026-09-23T10:00:04.000ZAbortion statistics in England and Waleshttps://www.pharmaradar360.com/article/exclusive-ai-biotech-enveda-doubles-in-value-to-2-billion-a869218d6b806c02PharmaRadar360en2026-09-23T10:00:00.000ZExclusive | AI Biotech Enveda Doubles in Value to $2 Billionhttps://www.pharmaradar360.com/article/jimmy-kimmel-trolls-trump-s-allies-with-parody-pharmaceutical-ad-b474764485d9f9c8PharmaRadar360en2026-09-23T09:59:51.000ZJimmy Kimmel trolls Trump's allies with parody pharmaceutical adhttps://www.pharmaradar360.com/article/polyurethane-tubing-for-biotech-market-to-2035-biopharma-capacity-expansion-driv-2c9779b6fa8fae8dPharmaRadar360en2026-09-23T09:46:23.000ZPolyurethane Tubing for Biotech Market To 2035: Biopharma Capacity Expansion Drives Growth - News and Statisticshttps://www.pharmaradar360.com/article/pharmaceutical-companies-push-trump-administration-to-protect-china-deals-40671ca1388c0776PharmaRadar360en2026-09-23T09:42:10.000ZPharmaceutical Companies Push Trump Administration to Protect China Dealshttps://www.pharmaradar360.com/article/testo-at-cphi-2026-in-milan-digital-monitoring-for-the-pharmaceutical-industry-51206cd2f0198a2fPharmaRadar360en2026-09-23T09:11:10.000ZTesto at CPHI 2026 in Milan: digital monitoring for the pharmaceutical industryhttps://www.pharmaradar360.com/article/nine-european-pharma-chairs-warn-of-slow-agony-as-investment-slips-1254cc631db64b03PharmaRadar360en2026-09-23T09:07:33.000ZNine European pharma chairs warn of 'slow agony' as investment slipshttps://www.pharmaradar360.com/article/doustdar-on-plunging-share-price-reflects-level-of-confidence-in-the-company-and-73e26491eface571PharmaRadar360en2026-09-23T09:04:22.000ZDoustdar on plunging share price: Reflects level of confidence in the company and its CEOhttps://www.pharmaradar360.com/article/field-safety-notices-14-to-18-september-2026-e1fc284848d2c91cPharmaRadar360en2026-09-23T09:03:48.000ZField Safety Notices: 14 to 18 September 2026https://www.pharmaradar360.com/article/otsuka-and-ionis-report-positive-phase-iii-readout-for-ulefnersen-36ca2d60798ce8dfPharmaRadar360en2026-09-23T09:01:48.000ZOtsuka and Ionis report positive Phase III readout for ulefnersenhttps://www.pharmaradar360.com/article/transparency-data-mhra-performance-data-d981698b76b6bbf6PharmaRadar360en2026-09-23T09:00:20.000ZTransparency data: MHRA Performance Datahttps://www.pharmaradar360.com/article/keep-britain-working-20e801e2a2496745PharmaRadar360en2026-09-23T08:58:51.000ZKeep Britain Workinghttps://www.pharmaradar360.com/article/drugmakers-biotech-vcs-show-reinvigorated-interest-in-osteoporosis-treatments-ed6a223fc4d8d0a9PharmaRadar360en2026-09-23T08:34:07.000ZDrugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatmentshttps://www.pharmaradar360.com/article/innovation-must-remain-at-the-heart-of-pandemic-prevention-preparedness-and-resp-3432662b985a1270PharmaRadar360en2026-09-23T08:22:29.000ZInnovation must remain at the heart of pandemic prevention, preparedness, and response, says pharma industryhttps://www.pharmaradar360.com/article/vaccine-update-issue-376-september-2026-d78aba8959192ee6PharmaRadar360en2026-09-23T08:19:03.000ZVaccine update: issue 376, September 2026https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-leaders-bfa3f2c240dbd84fPharmaRadar360en2026-09-23T08:18:48.000ZTop 10: Pharmaceutical Manufacturing Leadershttps://www.pharmaradar360.com/article/redweiler-480g-red-punch-redweiler-480g-orange-redweiler-480g-cola-tcm-120-mega-f98b8409bad1dccePharmaRadar360en2026-09-23T07:53:29.000ZΑπαγόρευση διάθεσης και διακίνησης των συμπληρωμάτων διατροφής REDWEILER 480G red punch, REDWEILER 480G orange, REDWEILER 480G cola, TCM 120 MEGA capshttps://www.pharmaradar360.com/article/annual-flu-programme-8d7750db1c23f662PharmaRadar360en2026-09-23T07:48:01.000ZAnnual flu programmehttps://www.pharmaradar360.com/article/medienmitteilung-die-bevolkerung-erwartet-einen-besseren-zugang-zu-innovativen-m-f83c269f70b8021fPharmaRadar360en2026-09-23T07:14:59.000ZMedienmitteilung: Die Bevölkerung erwartet einen besseren Zugang zu innovativen Medikamentenhttps://www.pharmaradar360.com/article/anaconda-biomed-snares-56m-in-funding-for-endovascular-tech-ec4619246ad794d9PharmaRadar360en2026-09-23T07:00:00.000ZAnaconda Biomed snares $56M in funding for endovascular techhttps://www.pharmaradar360.com/article/cbl-514-meets-primary-endpoint-in-phase-2-dercum-s-disease-trial-4aa1315c77b554dcPharmaRadar360en2026-09-23T06:53:08.000ZCBL-514 Meets Primary Endpoint in Phase 2 Dercum’s Disease Trialhttps://www.pharmaradar360.com/article/roche-s-sefaxersen-meets-primary-endpoint-in-phase-3-igan-study-8446d6133f8aa4caPharmaRadar360en2026-09-23T06:48:27.000ZRoche’s Sefaxersen Meets Primary Endpoint in Phase 3 IgAN Studyhttps://www.pharmaradar360.com/article/fda-lifts-clinical-hold-on-simufilam-for-tsc-related-epilepsy-study-eca3143a8c42883fPharmaRadar360en2026-09-23T06:48:26.000ZFDA Lifts Clinical Hold on Simufilam for TSC-Related Epilepsy Studyhttps://www.pharmaradar360.com/article/denmark-s-central-bank-sees-4-gdp-growth-in-2026-boosted-by-pharmaceutical-indus-ae01f315cf303771PharmaRadar360en2026-09-23T06:44:25.000ZDenmark's central bank sees 4% GDP growth in 2026, boosted by pharmaceutical industryhttps://www.pharmaradar360.com/article/wednesday-newspaper-round-up-state-pension-pharmaceutical-companies-bmw-22f669ea94e5958fPharmaRadar360en2026-09-23T06:05:54.000ZWednesday newspaper round-up: state pension, pharmaceutical companies, BMWhttps://www.pharmaradar360.com/article/argenx-arrowhead-incyte-and-other-moonshot-biotech-stocks-to-watch-6bcfcd137294b001PharmaRadar360en2026-09-23T05:45:00.000ZArgenx, Arrowhead, Incyte, and Other ‘Moonshot’ Biotech Stocks to Watchhttps://www.pharmaradar360.com/article/blood-stained-ice-found-at-gallops-in-mumbai-restaurant-deepika-padukone-hosted-d7c8d4be6fe7ad46PharmaRadar360en2026-09-23T05:41:05.000ZBlood Stained Ice Found At Gallops In Mumbai, Restaurant Deepika Padukone Hosted Her Fanshttps://www.pharmaradar360.com/article/hhs-unveils-new-initiatives-to-reduce-animal-testing-in-drug-development-dcfb867919371bddPharmaRadar360en2026-09-23T05:18:52.000ZHHS unveils new initiatives to reduce animal testing in drug developmenthttps://www.pharmaradar360.com/article/positive-interim-data-shows-roche-s-sefaxersen-significantly-reduces-proteinuria-18f5014a922c38adPharmaRadar360en2026-09-23T05:15:00.000ZPositive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)https://www.pharmaradar360.com/article/roche-proposes-former-takeda-ceo-for-board-seat-904ade392ec97c62PharmaRadar360en2026-09-23T05:12:00.000ZRoche proposes former Takeda CEO for board seathttps://www.pharmaradar360.com/article/pfizer-india-speaks-up-after-karnataka-fda-crackdown-says-patient-safety-is-top-2d42ea33dec63e93PharmaRadar360en2026-09-23T05:07:00.000ZPfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priorityhttps://www.pharmaradar360.com/article/a-kidney-disease-can-progress-to-kidney-failure-in-up-to-half-of-patients-within-b504c1b48ca0f4bdPharmaRadar360en2026-09-23T05:05:40.000ZA kidney disease can progress to kidney failure in up to half of patients within 20 years. Ionis' drug met its trial goal.https://www.pharmaradar360.com/article/change-in-roche-s-board-of-directors-3f66dadd4f0ce683PharmaRadar360en2026-09-23T05:00:00.000ZChange in Roche’s Board of Directorshttps://www.pharmaradar360.com/article/how-is-incyte-s-stock-performance-compared-to-other-biotech-stocks-217f74a05b95f6c6PharmaRadar360en2026-09-23T04:53:05.000ZHow Is Incyte’s Stock Performance Compared to Other Biotech Stocks?https://www.pharmaradar360.com/article/varda-space-industries-signs-steve-layne-as-chief-revenue-officer-and-aaron-hube-c7f0826d164cee9bPharmaRadar360en2026-09-23T04:37:11.000ZVarda Space Industries Signs Steve Layne as Chief Revenue Officer and Aaron Huber as Chief Financial Officerhttps://www.pharmaradar360.com/article/china-s-surging-biotech-sector-represents-both-competition-and-lifeline-for-the-3c127d71cc0c9a1ePharmaRadar360en2026-09-23T04:23:05.000ZChina’s surging biotech sector represents both competition and lifeline for the UShttps://www.pharmaradar360.com/article/china-clinical-trials-give-biotech-edge-us-concerns-grow-news-and-statistics-0f3c5f350061d556PharmaRadar360en2026-09-23T04:03:05.000ZChina Clinical Trials Give Biotech Edge; US Concerns Grow - News and Statisticshttps://www.pharmaradar360.com/article/biotech-is-one-area-where-the-us-can-afford-to-let-china-flourish-804a8a8a2ecb3155PharmaRadar360en2026-09-23T04:01:38.000ZBiotech is one area where the US can afford to let China flourishhttps://www.pharmaradar360.com/article/guggenheim-names-top-stock-pick-in-biotech-sector-b71fce6a39b3f0f4PharmaRadar360en2026-09-23T03:49:51.000ZGuggenheim Names Top Stock Pick in Biotech Sectorhttps://www.pharmaradar360.com/article/pca-girls-varsity-volleyball-vs-biotech-senior-32c8f64109110091PharmaRadar360en2026-09-23T03:45:35.000ZPCA Girls Varsity Volleyball vs. BioTECH Seniorhttps://www.pharmaradar360.com/article/a-share-market-update-pharmaceutical-stocks-surge-broadly-cansino-biologics-rise-8cc39d37a45eb156PharmaRadar360en2026-09-23T03:40:14.000ZA-Share Market Update: Pharmaceutical Stocks Surge Broadly; CanSino Biologics Rises Over 6%, Joinn Laboratories Up More Than 5%https://www.pharmaradar360.com/article/karnataka-fake-drug-case-pfizer-issues-statement-after-fda-revokes-licenses-of-1-21bf72b4a7e780a2PharmaRadar360en2026-09-23T03:05:25.000ZKarnataka fake drug case: Pfizer issues statement after FDA revokes licenses of 16 pharmacieshttps://www.pharmaradar360.com/article/better-healthcare-etf-invesco-s-biotech-focused-ibbq-vs-ishares-broad-iyh-cf62d79b13533fb7PharmaRadar360en2026-09-23T03:04:00.000ZBetter Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYHhttps://www.pharmaradar360.com/article/dementia-biotech-kinoxis-raises-6-75-million-with-a-2-5m-grant-as-cherry-on-top-75874c1badfd9fddPharmaRadar360en2026-09-23T02:44:01.000ZDementia biotech Kinoxis raises $6.75 million with a $2.5m grant as cherry on tophttps://www.pharmaradar360.com/article/jeil-pharmaceutical-s-onconic-begins-phase-3-trial-in-china-for-jaqubo-injectabl-fc3a04ac114cee7ePharmaRadar360en2026-09-23T02:39:40.000ZJeil Pharmaceutical's Onconic Begins Phase 3 Trial in China for Jaqubo Injectable, Secures $1 Million Milestonehttps://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-4359a68ab4882f23PharmaRadar360en2026-09-23T02:20:02.000ZThe drugs and devices have been on the market for years, but FDA-ordered studies still aren't donehttps://www.pharmaradar360.com/article/are-clinical-trials-about-to-become-a-new-front-in-the-us-china-biotech-race-4d06a653e66fe2bdPharmaRadar360en2026-09-23T02:00:09.000ZAre clinical trials about to become a new front in the US-China biotech race?https://www.pharmaradar360.com/article/pharmac-opens-recruitment-for-new-community-and-patient-advisory-committee-2a31f0e2b8d9a966PharmaRadar360en2026-09-23T02:00:00.000ZPharmac opens recruitment for new Community and Patient Advisory Committeehttps://www.pharmaradar360.com/article/onconic-s-zastaprazan-enters-phase-3-injectable-trial-in-china-c9376c3ab0540be3PharmaRadar360en2026-09-23T01:53:45.000ZOnconic’s zastaprazan enters phase 3 injectable trial in Chinahttps://www.pharmaradar360.com/article/pfizer-says-patient-safety-top-priority-amid-karnataka-fake-drug-probe-6fdf8d6d60f6d15cPharmaRadar360en2026-09-23T01:52:19.000ZPfizer Says Patient Safety Top Priority Amid Karnataka Fake Drug Probehttps://www.pharmaradar360.com/article/young-discusses-national-security-threats-at-fdd-5b739c7bae264418PharmaRadar360en2026-09-23T00:35:41.000ZYoung Discusses National Security Threats at FDDhttps://www.pharmaradar360.com/article/onconic-advances-ja-q-bo-in-china-as-phase-3-injection-starts-royalties-rise-cho-b856b83f3cc2b983PharmaRadar360en2026-09-23T00:10:00.000ZOnconic advances Ja Q Bo in China as phase 3 injection starts, royalties rise - CHOSUNBIZhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-16511f0f2ac5ad4fPharmaRadar360en2026-09-23T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-01b3e887f7dcead6PharmaRadar360en2026-09-23T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-4f5db2d73dc985cfPharmaRadar360en2026-09-23T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-10eeac13aab4c900PharmaRadar360en2026-09-23T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-f0eb7c639e6b7279PharmaRadar360en2026-09-23T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5670169091ce7e56PharmaRadar360en2026-09-23T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-eb184b78eb884466PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a093b591c8c1e790PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a5a2a3d18b030167PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-d97c25ec03b97152PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a92fc304b3f252b9PharmaRadar360en2026-09-23T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-735fad2b7cd0513dPharmaRadar360en2026-09-23T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-feeaac083dd2ed3bPharmaRadar360en2026-09-23T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-829dd417dc97be75PharmaRadar360en2026-09-23T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-96e00503aecd8ab9PharmaRadar360en2026-09-23T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/patient-protection-and-affordable-care-act-temporary-moratoria-on-certain-agent-5d843f42db06f8b8PharmaRadar360en2026-09-23T00:00:00.000ZPatient Protection and Affordable Care Act; Temporary Moratoria on Certain Agent and Broker Registration To Participate in the Exchangeshttps://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-9d0893d801a68de3PharmaRadar360en2026-09-23T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-neurological-disorders-and-stroke-notice-of-closed-meeting-1fac41b8e10220fbPharmaRadar360en2026-09-23T00:00:00.000ZNational Institute of Neurological Disorders and Stroke; Notice of Closed Meetinghttps://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-bc642d60aa107458PharmaRadar360en2026-09-23T00:00:00.000ZGovernment-Owned Inventions; Availability for Licensinghttps://www.pharmaradar360.com/article/sanjay-kumar-final-debarment-order-b205422749fd0e88PharmaRadar360en2026-09-23T00:00:00.000ZSanjay Kumar: Final Debarment Orderhttps://www.pharmaradar360.com/article/schedules-of-controlled-substances-placement-of-4-hydroxy-n-n-diisopropyltryptam-4e3caa3036ced2d5PharmaRadar360en2026-09-23T00:00:00.000ZSchedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule Ihttps://www.pharmaradar360.com/article/peer-review-report-for-impact-of-pharmacist-involvement-in-antimicrobial-steward-b6da4337dc8c16fcPharmaRadar360en2026-09-23T00:00:00.000ZPeer Review Report For: Impact of Pharmacist Involvement in Antimicrobial Stewardship Programs on Clinical Outcome and Antibiotic Utilization in Intensive Care Unit: A Systematic Review and Meta-Analysis [version 1; peer review: 1 not approved]https://www.pharmaradar360.com/article/neck-disability-associated-factors-and-quality-of-life-among-physiotherapists-in-49a201e66e78e7ebPharmaRadar360en2026-09-23T00:00:00.000ZNeck Disability, Associated Factors, and Quality of Life Among Physiotherapists in Saudi Arabiahttps://www.pharmaradar360.com/article/postoperative-c-reactive-protein-as-a-marker-of-the-early-inflammatory-response-875ae85d2ce71266PharmaRadar360en2026-09-23T00:00:00.000ZPostoperative C-Reactive Protein as a Marker of the Early Inflammatory Response in Robotic Versus Laparoscopic Minimally Invasive Surgery for Endometrial Cancer: A Propensity Score-Matched Analysishttps://www.pharmaradar360.com/article/short-term-safety-of-gastric-endoscopic-submucosal-dissection-in-patients-aged-8-4db1fa7ffa8f382bPharmaRadar360en2026-09-23T00:00:00.000ZShort-Term Safety of Gastric Endoscopic Submucosal Dissection in Patients Aged 80 Years or Older Under a Standardized Inpatient Post-Procedural Surveillance Pathway: Data from a 13-Year Real-World Cohort Studyhttps://www.pharmaradar360.com/article/a-multidimensional-assessment-of-cardiometabolic-risk-in-asian-americans-with-ch-03ad6b21bec4495cPharmaRadar360en2026-09-23T00:00:00.000ZA Multidimensional Assessment of Cardiometabolic Risk in Asian Americans with Chronic Hepatitis B Using the All of Us Datasetshttps://www.pharmaradar360.com/article/beyond-acquisition-quantifying-the-annual-carrying-cost-of-long-term-biospecimen-b9123924b47e7a6cPharmaRadar360en2026-09-23T00:00:00.000ZBeyond Acquisition: Quantifying the Annual Carrying Cost of Long-Term Biospecimen Storagehttps://www.pharmaradar360.com/article/paraprobiotics-and-postbiotics-from-mechanistic-evidence-to-food-applications-an-8f9399cd6bdd47ccPharmaRadar360en2026-09-23T00:00:00.000ZParaprobiotics and postbiotics: from mechanistic evidence to food applications and clinical translationhttps://www.pharmaradar360.com/article/editorial-explainable-artificial-intelligence-for-trustworthy-and-human-centric-ac82feba19738eaaPharmaRadar360en2026-09-23T00:00:00.000ZEditorial: Explainable artificial intelligence for trustworthy and human-centric healthcare: methods, evaluation, and clinical impacthttps://www.pharmaradar360.com/article/association-between-role-stress-and-job-burnout-among-clinical-research-nurses-a-b5aa08fccae4bfd4PharmaRadar360en2026-09-23T00:00:00.000ZAssociation between role stress and job burnout among clinical research nurses: a cross-sectional study in Chinahttps://www.pharmaradar360.com/article/therapist-self-report-reliability-and-accuracy-in-individual-vs-conjoint-systemi-e555b020dd335eddPharmaRadar360en2026-09-23T00:00:00.000ZTherapist self-report reliability and accuracy in individual vs. conjoint systemic family therapy sessions: implications for clinical monitoringhttps://www.pharmaradar360.com/article/optimal-prophylaxis-for-perioperative-drug-induced-delayed-neurocognitive-recove-5ca2615ca4e7f295PharmaRadar360en2026-09-23T00:00:00.000ZOptimal prophylaxis for perioperative drug-induced delayed neurocognitive recovery: a Bayesian network meta-analysis of 18 interventions with mechanism-based stratificationhttps://www.pharmaradar360.com/article/short-term-clinical-outcomes-associated-with-a-standardized-multicomponent-facia-e1801e946690bdbbPharmaRadar360en2026-09-23T00:00:00.000ZShort-term clinical outcomes associated with a standardized multicomponent facial rehabilitation program in acute or early-subacute peripheral facial nerve palsy: a prospective controlled cohort studyhttps://www.pharmaradar360.com/article/efficacy-of-anticoagulation-therapy-in-elderly-patients-with-clinically-diagnose-de416e1a65baf3d8PharmaRadar360en2026-09-23T00:00:00.000ZEfficacy of anticoagulation therapy in elderly patients with clinically diagnosed Alzheimer’s disease and atrial fibrillation: a clinical outcomes studyhttps://www.pharmaradar360.com/article/a-multimodal-machine-learning-diagnostic-model-for-alzheimer-s-disease-integrati-226cd8e46b6e3b46PharmaRadar360en2026-09-23T00:00:00.000ZA multimodal machine-learning diagnostic model for Alzheimer’s disease: integrating OCTA-derived retinal microvascular features and clinical variableshttps://www.pharmaradar360.com/article/biological-characterization-of-a-clinical-human-adenovirus-type-3-isolate-with-o-cdfc8156c517f734PharmaRadar360en2026-09-23T00:00:00.000ZBiological characterization of a clinical human adenovirus type 3 isolate with oncolytic potentialhttps://www.pharmaradar360.com/article/a-retrospective-cohort-study-predictive-nomogram-for-clinical-pregnancy-outcomes-3525205333fa2902PharmaRadar360en2026-09-23T00:00:00.000ZA retrospective cohort study: predictive nomogram for clinical pregnancy outcomes after intrauterine inseminationhttps://www.pharmaradar360.com/article/clinical-impact-of-early-enteral-nutrition-support-on-gastrointestinal-function-abe6b8b27c7ff208PharmaRadar360en2026-09-23T00:00:00.000ZClinical impact of early enteral nutrition support on gastrointestinal function, nutritional status, liver function, and immune function in liver cancer patientshttps://www.pharmaradar360.com/article/editorial-cellular-metabolism-the-immune-system-and-oncogenesis-opportunities-fo-f6f882b45b14e4b6PharmaRadar360en2026-09-23T00:00:00.000ZEditorial: Cellular metabolism, the immune system, and oncogenesis: opportunities for drug discovery and developmenthttps://www.pharmaradar360.com/article/clinical-and-epidemiological-profile-of-hospitalized-patients-with-leptospirosis-b7104dcb13cec58bPharmaRadar360en2026-09-23T00:00:00.000ZClinical and epidemiological profile of hospitalized patients with leptospirosis: a cross-sectional study in Durán, Ecuador, 2023https://www.pharmaradar360.com/article/metabolic-and-anthropometric-predictors-of-paediatric-metabolic-steatotic-liver-c04828fdbc62dda2PharmaRadar360en2026-09-23T00:00:00.000ZMetabolic and Anthropometric Predictors of Paediatric Metabolic Steatotic Liver Disease: Development of a Clinical Risk Prediction Modelhttps://www.pharmaradar360.com/article/uptake-barriers-and-facilitators-of-open-science-in-clinical-psychology-findings-e79006e53d98c6dePharmaRadar360en2026-09-23T00:00:00.000ZUptake, Barriers, and Facilitators of Open Science in Clinical Psychology: Findings from an Exploratory Survey in German-speaking Countrieshttps://www.pharmaradar360.com/article/addictive-escapism-in-the-context-of-fragmentation-of-value-semantic-space-drug-39c30a45b7c82bb5PharmaRadar360en2026-09-23T00:00:00.000ZAddictive Escapism in the Context of Fragmentation of Value-Semantic Space: Drug Addiction as a Postmodern Marker of Modern Youth Alienationhttps://www.pharmaradar360.com/article/peer-review-report-for-effect-of-a-community-based-intervention-for-cardiovascul-bffd3e087f4f828cPharmaRadar360en2026-09-23T00:00:00.000ZPeer Review Report For: Effect of a community-based intervention for cardiovascular risk factor control on stroke mortality in rural Gadchiroli, India: a cluster-randomised controlled trial [version 2; peer review: 2 approved, 1 approved with reservations]https://www.pharmaradar360.com/article/impact-of-timing-of-presentation-and-laparoscopic-findings-on-clinical-outcomes-99b32a220658c2efPharmaRadar360en2026-09-23T00:00:00.000ZImpact of Timing of Presentation and Laparoscopic Findings on Clinical Outcomes in Penetrating Abdominal Trauma: A Comparative Cohort Studyhttps://www.pharmaradar360.com/article/the-aimsi-protocol-study-protocol-of-a-randomized-double-blind-non-inferiority-c-0d2f973c86632267PharmaRadar360en2026-09-23T00:00:00.000ZThe AIMSI protocol: study protocol of a randomized, double-blind, non-inferiority clinical trial in dermocosmetics dedicated to atopic dermatitis (Lipikar®, La Roche-Posay vs. Relipid®, NEUTRADERM)https://www.pharmaradar360.com/article/a-four-tier-anti-hcv-hcv-rna-interpretation-grid-for-risk-selected-clinical-popu-0462e6238c73bb27PharmaRadar360en2026-09-23T00:00:00.000ZA four-tier anti-HCV / HCV-RNA interpretation grid for risk-selected clinical populations: a Bayesian sensitivity analysis defining its valid operating rangehttps://www.pharmaradar360.com/article/immediate-analgesic-effect-of-cheek-acupuncture-vs-etoricoxib-for-patients-with-1f433045c616e8d5PharmaRadar360en2026-09-23T00:00:00.000ZImmediate analgesic effect of cheek acupuncture vs etoricoxib for patients with acute gouty flare: a randomized controlled trialhttps://www.pharmaradar360.com/article/recombinase-polymerase-amplification-coupled-with-crispr-cas12a-for-rapid-detect-9088f98caabcd613PharmaRadar360en2026-09-23T00:00:00.000ZRecombinase Polymerase Amplification Coupled with CRISPR-Cas12a for Rapid Detection of Ciprofloxacin-Resistance Mutations in Clinical Urinary Isolateshttps://www.pharmaradar360.com/article/treatment-status-influences-circulating-microrna-expression-and-their-clinical-a-330230b34efa50aePharmaRadar360en2026-09-23T00:00:00.000ZTreatment status influences circulating microRNA expression and their clinical and radiological associations in multiple sclerosishttps://www.pharmaradar360.com/article/comparison-of-clinical-characteristics-species-composition-and-antimicrobial-res-ad48db0c75ecfcadPharmaRadar360en2026-09-23T00:00:00.000ZComparison of clinical characteristics, species composition and antimicrobial resistance in extrapulmonary nontuberculous mycobacteria with or without HIV co-infectionhttps://www.pharmaradar360.com/article/cell-free-therapies-emerging-applications-of-extracellular-vesicles-and-secretom-0eb0c307fb10fd9dPharmaRadar360en2026-09-23T00:00:00.000ZCell-free therapies: Emerging applications of extracellular vesicles and secretomes in regenerative medicinehttps://www.pharmaradar360.com/article/legal-organizational-and-financial-mechanisms-for-providing-medicines-not-includ-adcb8486b171831bPharmaRadar360en2026-09-23T00:00:00.000ZLegal, organizational and financial mechanisms for providing medicines not included in the list of vital and essential drugs in the State guaranteed free medical care program for citizens (using anticancer drug therapy as an example)https://www.pharmaradar360.com/article/leveraging-long-read-sequencing-to-bridge-the-diagnostic-and-equity-gaps-in-diff-e2cbefef207ca413PharmaRadar360en2026-09-23T00:00:00.000ZLeveraging Long-Read Sequencing to Bridge the Diagnostic and Equity Gaps in Differences of Sex Development (DSD)https://www.pharmaradar360.com/article/letter-to-the-editor-from-y-lmaz-et-al-the-free-t3-free-t4-ratio-predicts-relaps-73b9efa36fc223a3PharmaRadar360en2026-09-23T00:00:00.000ZLetter to the Editor from Yılmaz et al.: “The Free T3/Free T4 Ratio Predicts Relapse After Antithyroid Drug Withdrawal in Pediatric Autoimmune Hyperthyroidism”https://www.pharmaradar360.com/article/dna-methylation-dysregulation-in-ebv-associated-lymphoproliferative-disorders-mo-5a356c91440576fdPharmaRadar360en2026-09-23T00:00:00.000ZDNA methylation dysregulation in EBV-associated lymphoproliferative disorders: molecular mechanisms and therapeutic advanceshttps://www.pharmaradar360.com/article/a-note-on-patient-follow-up-time-distribution-in-clinical-trial-simulations-with-d0133161e4e00572PharmaRadar360en2026-09-23T00:00:00.000ZA note on patient follow-up time distribution in clinical trial simulations with survival endpointshttps://www.pharmaradar360.com/article/clinical-characteristics-treatments-and-outcomes-of-patients-with-ornithine-tran-a1c88d6d32ef3a51PharmaRadar360en2026-09-23T00:00:00.000ZClinical characteristics, treatments and outcomes of patients with ornithine transcarbamylase deficiency (OTCD): a retrospective cohort study using a US electronic health record databasehttps://www.pharmaradar360.com/article/adherence-to-treat-to-target-recommendations-in-juvenile-idiopathic-arthritis-in-84176e3cd58018edPharmaRadar360en2026-09-23T00:00:00.000ZAdherence to treat-to-target recommendations in juvenile idiopathic arthritis in clinical practicehttps://www.pharmaradar360.com/article/precise-repair-of-extremity-soft-tissue-defects-using-anterolateral-thigh-flaps-ec30ab4fc6df8f00PharmaRadar360en2026-09-23T00:00:00.000ZPrecise repair of extremity soft tissue defects using anterolateral thigh flaps based on CTA-based 3D reconstruction and digital design: a short-term retrospective clinical studyhttps://www.pharmaradar360.com/article/i-invited-commentary-on-i-kandathil-et-al-s-postoperative-pain-management-in-rhi-658daec99b991957PharmaRadar360en2026-09-23T00:00:00.000Z<i>Invited Commentary on:</i> Kandathil et al.’s “Postoperative Pain Management in Rhinoplasty: A Double Blind Randomized Controlled Trial”https://www.pharmaradar360.com/article/phenolic-mannich-bases-review-on-synthetic-aspects-and-biological-activity-profi-61a6f71ecb860f68PharmaRadar360en2026-09-23T00:00:00.000ZPhenolic Mannich Bases: Review on Synthetic Aspects and Biological Activity Profileshttps://www.pharmaradar360.com/article/red-blood-cell-aggregation-and-atherosclerosis-curvilinear-clinical-implications-ef768b300cdbacbePharmaRadar360en2026-09-23T00:00:00.000ZRed blood cell aggregation and atherosclerosis: Curvilinear clinical implicationshttps://www.pharmaradar360.com/article/defining-near-term-treatment-goals-for-benzodiazepine-use-in-clinical-practice-04a3e19325e3d4f7PharmaRadar360en2026-09-23T00:00:00.000ZDefining Near-Term Treatment Goals for Benzodiazepine Use in Clinical Practicehttps://www.pharmaradar360.com/article/reduced-antibiotic-exposure-is-not-equivalent-to-reduced-antibiotic-overuse-afte-befc1cf0c44de4bfPharmaRadar360en2026-09-23T00:00:00.000ZReduced Antibiotic Exposure Is Not Equivalent to Reduced Antibiotic Overuse After Nirsevimabhttps://www.pharmaradar360.com/article/fully-ablative-co2-laser-excision-of-cutaneous-lesions-a-case-series-including-p-61eadbc7ce6135faPharmaRadar360en2026-09-23T00:00:00.000ZFully ablative CO2 laser excision of cutaneous lesions: A case series including patients with cardiac implantable electronic deviceshttps://www.pharmaradar360.com/article/the-clinical-benefit-of-routine-pet-ct-imaging-in-asymptomatic-head-and-neck-squ-a01c2272b379ada0PharmaRadar360en2026-09-23T00:00:00.000ZThe clinical benefit of routine PET/CT imaging in asymptomatic head and neck squamous cell cancer patients one year post-treatmenthttps://www.pharmaradar360.com/article/practical-lessons-in-the-global-scaling-of-clinical-ai-from-one-hospital-to-over-d823dc98459196b5PharmaRadar360en2026-09-23T00:00:00.000ZPractical lessons in the global scaling of clinical AI: from one hospital to over a million patients screenedhttps://www.pharmaradar360.com/article/systemic-and-mucosal-antibody-responses-against-neisseria-gonorrhoeae-ng-outer-m-7a0211afbe545718PharmaRadar360en2026-09-23T00:00:00.000ZSystemic and Mucosal Antibody Responses Against Neisseria gonorrhoeae (Ng) Outer Membrane Vesicle Antigens following Four-Component Meningococcal Serogroup B (4CMenB) Immunization in Healthy Adults: A Randomized Phase II Trialhttps://www.pharmaradar360.com/article/comparative-efficacy-and-safety-of-cd19-chimeric-antigen-receptor-t-cell-therapy-bc4ebc4c756dba65PharmaRadar360en2026-09-23T00:00:00.000ZComparative efficacy and safety of CD19 chimeric antigen receptor T-cell therapy versus CD3/CD20 bispecific antibodies in relapsed/refractory mantle cell lymphoma: a meta-analysis of clinical trials and real-world studieshttps://www.pharmaradar360.com/article/asymmetrical-consent-in-ambient-clinical-ai-rethinking-patient-recording-rights-e70ad24154760143PharmaRadar360en2026-09-23T00:00:00.000ZAsymmetrical consent in ambient clinical AI: rethinking patient recording rights and epistemic authority in U.S. health carehttps://www.pharmaradar360.com/article/carotid-intima-media-thickness-in-beta-thalassemia-a-systematic-review-and-meta-305f74b84c51fd60PharmaRadar360en2026-09-23T00:00:00.000ZCarotid Intima-Media Thickness in Beta-Thalassemia: A Systematic Review and Meta-Analysis of Patients Versus Healthy Controls and Clinical–Biochemical Correlateshttps://www.pharmaradar360.com/article/predictors-of-morbidity-and-mortality-in-malignancy-related-ascitic-fluid-infect-d88edb300cf290a3PharmaRadar360en2026-09-23T00:00:00.000ZPredictors of Morbidity and Mortality in Malignancy-Related Ascitic Fluid Infection: an Exploratory Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/pharmacotherapy-of-irritable-bowel-syndrome-with-constipation-in-children-an-upd-afbf506f2debfc3cPharmaRadar360en2026-09-23T00:00:00.000ZPharmacotherapy of Irritable Bowel Syndrome with Constipation in Children: An Update on Clinical Progress and Successeshttps://www.pharmaradar360.com/article/effect-of-preoperative-pain-neuroscience-education-on-pain-catastrophizing-and-e-421cbac901807b13PharmaRadar360en2026-09-23T00:00:00.000ZEffect of preoperative pain neuroscience education on pain catastrophizing and early recovery following upper extremity orthopaedic surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/performance-status-over-chronology-determinants-of-curative-versus-palliative-tr-13b5296c766e71c2PharmaRadar360en2026-09-23T00:00:00.000ZPerformance status over chronology: determinants of curative versus palliative treatment intent in older adults with gastrointestinal cancerhttps://www.pharmaradar360.com/article/improving-adaptation-in-male-high-altitude-workers-through-pressurization-a-rand-5bafac1786fd222cPharmaRadar360en2026-09-23T00:00:00.000ZImproving adaptation in male high-altitude workers through pressurization: a randomized controlled trial on sleep architecturehttps://www.pharmaradar360.com/article/ranibizumab-port-delivery-system-for-neovascular-age-related-macular-degeneratio-d7aa2ef6ee7adaaePharmaRadar360en2026-09-23T00:00:00.000ZRanibizumab port delivery system for neovascular age-related macular degeneration: Current evidence and surgical considerationshttps://www.pharmaradar360.com/article/procomb-a-practical-and-robust-design-with-randomization-to-optimize-dose-combin-290fbb808edc5459PharmaRadar360en2026-09-23T00:00:00.000ZPROComb: A Practical and Robust Design With Randomization to Optimize Dose Combinations in Drug Combination Trialshttps://www.pharmaradar360.com/article/impact-of-sickle-cell-hemoglobin-genotypes-on-clinical-outcomes-among-i-plasmodi-d38e4ae0b0ee8c10PharmaRadar360en2026-09-23T00:00:00.000ZImpact of Sickle Cell Hemoglobin Genotypes on Clinical Outcomes Among <i>Plasmodium falciparum</i> Malaria Patients in Luanda, Angolahttps://www.pharmaradar360.com/article/volumetric-modulated-arc-therapy-for-lung-cancer-correlation-between-dose-and-vo-6490752166bf0195PharmaRadar360en2026-09-23T00:00:00.000ZVolumetric Modulated Arc Therapy for lung cancer: Correlation between dose and volumehttps://www.pharmaradar360.com/article/rocket-pharmaceuticals-rckt-gets-fda-alignment-on-heart-drug-trial-can-it-ease-s-9277c4a585be2689PharmaRadar360en2026-09-22T23:52:21.000ZRocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?https://www.pharmaradar360.com/article/keep-britain-working-review-update-a-national-growth-opportunity-september-2026-b449a68a7ec408e5PharmaRadar360en2026-09-22T23:01:04.000ZKeep Britain Working review update: a national growth opportunity, September 2026https://www.pharmaradar360.com/article/as-stigma-fades-reverse-mergers-boom-in-biotech-174a6012d4b759f8PharmaRadar360en2026-09-22T22:59:00.000ZAs Stigma Fades, Reverse Mergers Boom In Biotechhttps://www.pharmaradar360.com/article/fda-takes-issue-with-empower-pharmacy-s-glp-1-production-in-new-warning-letter-bbcc7bc0792288c1PharmaRadar360en2026-09-22T22:48:58.000ZFDA takes issue with Empower Pharmacy's GLP-1 production in new warning letterhttps://www.pharmaradar360.com/article/the-overlooked-role-of-containers-in-chemical-and-pharmaceutical-operations-d9a479d7a99df2f6PharmaRadar360en2026-09-22T22:09:44.000ZThe overlooked role of containers in chemical and pharmaceutical operationshttps://www.pharmaradar360.com/article/eli-lilly-breaks-ground-on-6-5b-houston-pharmaceutical-manufacturing-facility-9c9b191a0f0915cdPharmaRadar360en2026-09-22T21:44:15.000ZEli Lilly Breaks Ground on $6.5B Houston Pharmaceutical Manufacturing Facilityhttps://www.pharmaradar360.com/article/china-s-yipin-pharmaceutical-raises-tens-of-millions-in-yuan-for-anaesthetics-pu-df3f73952434bb15PharmaRadar360en2026-09-22T21:18:04.000ZChina's Yipin Pharmaceutical raises tens of millions in yuan for anaesthetics pushhttps://www.pharmaradar360.com/article/biopharma-biological-safety-cabinets-aseptic-technique-for-sterile-drug-manufact-50ac51026318a92aPharmaRadar360en2026-09-22T20:51:57.000ZBiopharma Biological Safety Cabinets: Aseptic Technique for Sterile Drug Manufacturinghttps://www.pharmaradar360.com/article/vht-vs-xbi-is-diversified-healthcare-exposure-or-biotech-stocks-the-smarter-choi-0db424becee8ba71PharmaRadar360en2026-09-22T20:41:00.000ZVHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors?https://www.pharmaradar360.com/article/amgen-drug-meets-goals-of-key-test-in-common-autoimmune-disease-with-no-approved-562c53f4bdd9952bPharmaRadar360en2026-09-22T20:03:34.000ZAmgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Medshttps://www.pharmaradar360.com/article/human-cell-tests-and-computer-models-gain-formal-place-in-fda-rules-for-drug-saf-4288d02f95194a5dPharmaRadar360en2026-09-22T20:00:12.000ZHuman Cell Tests and Computer Models Gain Formal Place in FDA Rules for Drug Safety Before First Trialshttps://www.pharmaradar360.com/article/celldex-therapeutics-upgraded-to-buy-after-posi-03401a823e3c1eb5PharmaRadar360en2026-09-22T19:59:20.000ZCelldex Therapeutics upgraded to Buy after posi...https://www.pharmaradar360.com/article/cordis-project-a-precision-medicine-trial-leveraging-blood-based-tumor-genomics-832a33c89b017818PharmaRadar360en2026-09-22T19:58:05.000ZCORDIS project: A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE SAGITTARIUS TRIALhttps://www.pharmaradar360.com/article/cordis-project-european-african-vaccine-initiative-eavi-accelerating-preventive-450f5665b25341fdPharmaRadar360en2026-09-22T19:55:28.000ZCORDIS project: EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICAhttps://www.pharmaradar360.com/article/cordis-project-services-for-environmental-exposure-and-health-assessment-in-euro-53b48a7be88525abPharmaRadar360en2026-09-22T19:54:00.000ZCORDIS project: Services for envIRonmental Exposure and health assessmeNt in Europehttps://www.pharmaradar360.com/article/on-the-job-training-program-helps-greenwood-resident-into-biotech-career-811eb59219a9358cPharmaRadar360en2026-09-22T19:53:52.000ZOn the job: Training program helps Greenwood resident into biotech careerhttps://www.pharmaradar360.com/article/direxion-daily-s-p-biotech-bear-3x-shares-declares-quarterly-distribution-of-0-0-ccfddfb80ed3a79aPharmaRadar360en2026-09-22T19:52:37.000ZDirexion Daily S&P Biotech Bear 3X Shares declares quarterly distribution of $0.0707https://www.pharmaradar360.com/article/ulefnersen-meets-primary-end-point-in-phase-3-fusion-trial-for-fus-als-004c41caee9d8e4ePharmaRadar360en2026-09-22T19:41:44.000ZUlefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALShttps://www.pharmaradar360.com/article/legend-biotech-nasdaq-legn-shareholder-plans-2-715-ads-rule-144-sale-841a12d86e050982PharmaRadar360en2026-09-22T19:31:02.000ZLegend Biotech (NASDAQ: LEGN) shareholder plans 2,715-ADS Rule 144 salehttps://www.pharmaradar360.com/article/amgen-reports-a-phase-3-win-with-sjogren-s-drug-candidate-4d19987a7b90f4bdPharmaRadar360en2026-09-22T19:06:44.000ZAmgen reports a Phase 3 win with Sjögren’s drug candidatehttps://www.pharmaradar360.com/article/major-nj-pharmaceutical-company-lays-off-hundreds-9bb21c3e4fe5cb52PharmaRadar360en2026-09-22T19:03:46.000ZMajor NJ Pharmaceutical Company Lays Off Hundredshttps://www.pharmaradar360.com/article/nine-european-drugmakers-note-concern-over-region-s-pharma-investments-pharmexec-d2f1bdf40f76425dPharmaRadar360en2026-09-22T19:02:22.000ZNine European Drugmakers Note Concern Over Region's Pharma Investments | PharmExechttps://www.pharmaradar360.com/article/european-drugmakers-say-they-are-losing-ground-to-us-and-chinese-rivals-0d402f8f3ef33843PharmaRadar360en2026-09-22T18:51:00.000ZEuropean drugmakers say they are ‘losing ground’ to US and Chinese rivalshttps://www.pharmaradar360.com/article/former-legend-biotech-nasdaq-legn-officer-lines-up-1-3m-stock-sale-a09773669bac8e93PharmaRadar360en2026-09-22T18:34:08.000ZFormer Legend Biotech (NASDAQ: LEGN) officer lines up $1.3M stock salehttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-builds-oncology-pipeline-around-bitac-platform-public-market-f355446610826911PharmaRadar360en2026-09-22T18:30:00.000ZVERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phasehttps://www.pharmaradar360.com/article/did-ceo-appointment-just-shift-legend-biotech-stock-investment-narrative-39b39a15e61896b9PharmaRadar360en2026-09-22T18:06:02.000ZDid CEO Appointment Just Shift Legend Biotech Stock Investment Narrative?https://www.pharmaradar360.com/article/caris-life-sciences-coasts-past-a-buy-point-why-this-texas-biotech-researcher-de-bc7b2a82a6bfdea0PharmaRadar360en2026-09-22T18:01:00.000ZCaris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Lookhttps://www.pharmaradar360.com/article/fda-updates-rules-to-advance-non-animal-innovative-testing-in-human-drug-develop-c6422f067acfdab8PharmaRadar360en2026-09-22T17:47:38.000ZFDA updates rules to advance non-animal, innovative testing in human drug developmenthttps://www.pharmaradar360.com/article/novartis-secures-new-radioligand-in-900m-deal-as-competition-strengthens-50d67d023b86cc61PharmaRadar360en2026-09-22T17:22:27.000ZNovartis secures new radioligand in $900M deal as competition strengthenshttps://www.pharmaradar360.com/article/cordis-project-representative-clinical-research-advancing-inclusivity-in-europe-ce5cc956533fb572PharmaRadar360en2026-09-22T17:18:58.000ZCORDIS project: REpresentative Clinical Research - ADvancing Inclusivity in Europehttps://www.pharmaradar360.com/article/karnataka-suspends-assistant-drug-controller-over-alleged-lapses-in-counterfeit-954ba4d2ecda5f99PharmaRadar360en2026-09-22T17:01:26.000ZKarnataka Suspends Assistant Drug Controller Over Alleged Lapses in Counterfeit Drug Casehttps://www.pharmaradar360.com/article/cordis-project-an-innovative-analytical-platform-to-investigate-the-effect-and-t-22d02dfce8336ab4PharmaRadar360en2026-09-22T16:48:32.000ZCORDIS project: AN INNOVATIVE ANALYTICAL PLATFORM TO INVESTIGATE THE EFFECT AND TOXICITY OF MICRO AND NANO PLASTICS COMBINED WITH ENVIRONMENTAL CONTAMINANTS ON THE RISK OF ALLERGIC DISEASE IN PRECLINICAL AND CLINICALhttps://www.pharmaradar360.com/article/cordis-project-autism-innovative-medicine-studies-2-trials-36292d3d44288306PharmaRadar360en2026-09-22T16:48:32.000ZCORDIS project: Autism Innovative Medicine Studies – 2 – Trialshttps://www.pharmaradar360.com/article/vertex-s-kidney-drug-success-sparks-a-22-surge-for-this-rival-biotech-860d4568cb022503PharmaRadar360en2026-09-22T16:46:00.000ZVertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotechhttps://www.pharmaradar360.com/article/fda-modernizes-drug-regulations-to-formalize-support-for-nams-7dde384d2183288cPharmaRadar360en2026-09-22T16:15:23.000ZFDA modernizes drug regulations to formalize support for NAMshttps://www.pharmaradar360.com/article/fake-medicine-racket-assistant-drug-controller-omkareshwar-suspended-aa6b284cdda1363bPharmaRadar360en2026-09-22T15:57:07.000ZFake Medicine Racket:Assistant Drug Controller Omkareshwar Suspendedhttps://www.pharmaradar360.com/article/fda-updates-rule-on-animal-testing-for-new-drugs-98a07a874a31de1bPharmaRadar360en2026-09-22T15:52:55.000ZFDA Updates Rule on Animal Testing for New Drugshttps://www.pharmaradar360.com/article/food-drug-crackdowns-test-india-s-regulatory-enforcement-muscle-ba2109dbf55a7346PharmaRadar360en2026-09-22T15:48:29.000ZFood, drug crackdowns test India's regulatory enforcement musclehttps://www.pharmaradar360.com/article/fda-updates-drug-safety-testing-rules-to-embrace-non-animal-methods-cedfedd050abc998PharmaRadar360en2026-09-22T15:38:39.000ZFDA updates drug safety testing rules to embrace non-animal methodshttps://www.pharmaradar360.com/article/generic-drug-user-fee-reauthorization-amidst-alleged-concerns-of-safety-and-effi-c661778b45f1c06ePharmaRadar360en2026-09-22T15:38:36.000ZGeneric Drug User Fee Reauthorization Amidst Alleged Concerns of Safety and Efficacyhttps://www.pharmaradar360.com/article/abbvie-participates-in-ustr-s-section-301-investigation-into-germany-to-address-e44e409ff6d1d1c8PharmaRadar360en2026-09-22T15:36:00.000ZAbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valuedhttps://www.pharmaradar360.com/article/why-temperature-control-is-now-pharma-s-make-or-break-variable-0b39008986dae1a7PharmaRadar360en2026-09-22T15:34:06.000ZWhy Temperature Control Is Now Pharma’s Make-or-Break Variablehttps://www.pharmaradar360.com/article/ionis-otsuka-s-phase-3-win-in-als-subtype-boehringer-s-up-to-1b-cancer-deal-c9153ce71a34dadfPharmaRadar360en2026-09-22T15:29:00.000ZIonis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer dealhttps://www.pharmaradar360.com/article/zealand-pharma-announces-initiation-of-the-registrational-phase-3-zupreme-progra-478c3cbbf4c8be0cPharmaRadar360en2026-09-22T15:15:49.000ZZealand Pharma announces initiation of the registrational Phase 3 ZUPREME program of petrelintide in people with overweight or obesityhttps://www.pharmaradar360.com/article/amgen-inc-stock-amgn-moved-up-by-3-90-on-sep-22-facts-behind-the-movement-638e1517a3957b7dPharmaRadar360en2026-09-22T15:15:23.000ZAmgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movementhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4PharmaRadar360en2026-09-22T15:06:44.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/rotavirus-vaccination-programme-information-for-healthcare-practitioners-53785302d776c5f3PharmaRadar360en2026-09-22T15:00:29.000ZRotavirus vaccination programme: information for healthcare practitionershttps://www.pharmaradar360.com/article/5-reasons-to-have-your-flu-vaccine-when-pregnant-poster-617282f23f9f2cc4PharmaRadar360en2026-09-22T14:59:07.000Z5 reasons to have your flu vaccine when pregnant posterhttps://www.pharmaradar360.com/article/ukhsa-spend-over-25-000-2026-a8b4b8d9bbff80c2PharmaRadar360en2026-09-22T14:58:05.000ZUKHSA spend over £25,000: 2026https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20cePharmaRadar360en2026-09-22T14:56:40.000ZAntimicrobial resistance awareness: toolkit for healthcare providershttps://www.pharmaradar360.com/article/should-you-buy-moderna-stock-why-many-wall-street-analysts-say-no-9e67b14c2180f083PharmaRadar360en2026-09-22T14:53:00.000ZShould You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."https://www.pharmaradar360.com/article/4-biotech-stocks-with-key-clinical-readouts-expected-this-fall-fdfbfae8d3ac9708PharmaRadar360en2026-09-22T14:51:00.000Z4 Biotech Stocks With Key Clinical Readouts Expected This Fallhttps://www.pharmaradar360.com/article/nvidia-backed-iambic-files-for-ipo-disclosing-new-clinic-and-dealmaking-details-9081c31813b92024PharmaRadar360en2026-09-22T14:37:00.000ZNvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking detailshttps://www.pharmaradar360.com/article/novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge-program-0be7d11290c417d3PharmaRadar360en2026-09-22T14:26:39.000ZNovo may be getting a better deal than expected with Medicare’s Bridge programhttps://www.pharmaradar360.com/article/2026-ipo-blitz-continues-with-4-new-biotech-filings-347251671248c048PharmaRadar360en2026-09-22T14:23:05.000Z2026 IPO blitz continues with 4 new biotech filingshttps://www.pharmaradar360.com/article/amgen-s-horizon-acquired-fusion-protein-eases-sjogren-s-severity-in-ph-3-win-fabca74fb5c275a3PharmaRadar360en2026-09-22T14:20:43.000ZAmgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 winhttps://www.pharmaradar360.com/article/ukhsa-and-pace-make-new-bacteria-available-to-support-research-into-tackling-ant-03949b464e5bf1c5PharmaRadar360en2026-09-22T14:19:10.000ZUKHSA and PACE make new bacteria available to support research into tackling antimicrobial resistancehttps://www.pharmaradar360.com/article/new-preliminary-positive-data-from-open-label-extension-of-phase-3-study-fasedie-a43f8824c131b981PharmaRadar360en2026-09-22T14:14:56.000ZNew Preliminary Positive Data From Open-Label Extension of Phase 3 Study: Fasedienol for the Acute Treatment of Social Anxiety Disorderhttps://www.pharmaradar360.com/article/how-stakeholders-can-avert-340b-rebate-disruption-766ebeb8cd517505PharmaRadar360en2026-09-22T14:14:37.000ZHow Stakeholders Can Avert 340B Rebate Disruptionhttps://www.pharmaradar360.com/article/ionis-announces-positive-topline-results-from-phase-3-fusion-study-of-ulefnersen-772a4e1e1109bf31PharmaRadar360en2026-09-22T14:11:13.000ZIonis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALShttps://www.pharmaradar360.com/article/otsuka-announces-transformative-phase-3-fusion-results-for-ulefnersen-bringing-t-b70c8b2f7386a8a2PharmaRadar360en2026-09-22T14:11:12.000ZOtsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatmenthttps://www.pharmaradar360.com/article/travere-ceo-eric-dube-to-step-down-after-transforming-the-rare-disease-biotech-89bdf641a2b15d7cPharmaRadar360en2026-09-22T14:10:57.000ZTravere CEO Eric Dube to step down after transforming the rare disease biotechhttps://www.pharmaradar360.com/article/vertex-s-midstage-data-amplify-kidney-disease-market-opportunity-523fc055ccc416fcPharmaRadar360en2026-09-22T14:09:48.000ZVertex’s midstage data amplify kidney disease market opportunityhttps://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64PharmaRadar360en2026-09-22T14:07:50.000ZDrug Alerts and Statementshttps://www.pharmaradar360.com/article/fda-publishes-2026-food-code-c8977096a5309312PharmaRadar360en2026-09-22T14:07:43.000ZFDA Publishes 2026 Food Codehttps://www.pharmaradar360.com/article/merck-sued-with-former-lot-network-canon-patent-by-biotech-npe-181c0bc7aa670f0ePharmaRadar360en2026-09-22T14:03:22.000ZMerck sued with former LOT Network/Canon patent by biotech NPEhttps://www.pharmaradar360.com/article/changes-to-the-definition-of-deprivation-of-liberty-6ef57301ec10516ePharmaRadar360en2026-09-22T13:52:04.000ZChanges to the definition of deprivation of libertyhttps://www.pharmaradar360.com/article/what-is-ibogaine-all-about-the-psychoactive-drug-presley-gerber-took-for-treatme-10da3bcc8d406517PharmaRadar360en2026-09-22T13:52:00.000ZWhat is ibogaine? All about the psychoactive drug Presley Gerber took for treatment before deathhttps://www.pharmaradar360.com/article/x-chem-announces-phase-3-milestone-in-collaboration-with-relay-therapeutics-2ed0320843199e26PharmaRadar360en2026-09-22T13:51:41.000ZX-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeuticshttps://www.pharmaradar360.com/article/from-the-classroom-to-research-rethinking-school-non-attendance-as-a-complex-pub-370891176b9691edPharmaRadar360en2026-09-22T13:47:48.000ZFrom the Classroom to Research: Rethinking School Non-Attendance as a Complex Public Health Issuehttps://www.pharmaradar360.com/article/roche-obesity-drug-enicepatide-delivers-15-5-weight-loss-in-phase-2-diabetes-tri-456c0904bdf4161ePharmaRadar360en2026-09-22T13:42:48.000ZRoche Obesity Drug Enicepatide Delivers 15.5% Weight Loss in Phase 2 Diabetes Trialhttps://www.pharmaradar360.com/article/amgen-s-dazodalibep-phase-3-trial-clears-sjogren-s-hurdle-ce20313f496b35b5PharmaRadar360en2026-09-22T13:32:43.000ZAmgen’s dazodalibep Phase 3 trial clears Sjögren’s hurdlehttps://www.pharmaradar360.com/article/a-proposed-law-could-give-qualifying-botanical-drugs-12-years-of-market-exclusiv-49f868a028738c3dPharmaRadar360en2026-09-22T13:30:00.000ZA proposed law could give qualifying botanical drugs 12 years of market exclusivity. Endovia closes funding.https://www.pharmaradar360.com/article/comienza-en-lisboa-el-xv-encuentro-de-la-red-eami-con-el-objetivo-de-establecer-a43077edfe8b6eadPharmaRadar360en2026-09-22T13:23:40.000ZComienza en Lisboa el XV Encuentro de la Red EAMI con el objetivo de establecer nuevas vías de cooperación y fortalecimiento regulatorio entre las autoridades de medicamentos de Iberoaméricahttps://www.pharmaradar360.com/article/otsuka-heads-to-fda-as-ionis-partnered-als-drug-hits-primary-phase-3-endpoint-7548c69d954fe247PharmaRadar360en2026-09-22T13:22:17.000ZOtsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpointhttps://www.pharmaradar360.com/article/tb-bcg-and-your-baby-74fb0616222bda49PharmaRadar360en2026-09-22T13:05:36.000ZTB, BCG and your babyhttps://www.pharmaradar360.com/article/sjogren-s-disease-has-no-fda-approved-medicines-amgen-s-treatment-improved-disea-be1c1e5896371af6PharmaRadar360en2026-09-22T13:02:30.000ZSjögren’s disease has no FDA-approved medicines. Amgen’s treatment improved disease activity in a trial.https://www.pharmaradar360.com/article/psychedelic-depression-and-ptsd-trials-get-new-lead-at-optimi-health-opth-41c95a683e26fe4ePharmaRadar360en2026-09-22T13:00:50.000ZPsychedelic depression and PTSD trials get new lead at Optimi Health (OPTH)https://www.pharmaradar360.com/article/optimi-health-appoints-dr-michael-blough-as-chief-clinical-development-officer-b962f1ca3661de64PharmaRadar360en2026-09-22T13:00:00.000ZOptimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officerhttps://www.pharmaradar360.com/article/a-lung-cancer-treatment-showed-90-5-disease-control-in-an-interim-trial-assessme-65b591b14180f7f7PharmaRadar360en2026-09-22T12:47:00.000ZA lung cancer treatment showed 90.5% disease control in an interim trial assessmenthttps://www.pharmaradar360.com/article/maia-biotechnology-reports-pivotal-phase-3-clinical-trial-progress-in-advanced-n-d50277e15a8ec3c4PharmaRadar360en2026-09-22T12:47:00.000ZMAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/preliminary-data-social-anxiety-scores-improved-31-points-in-four-months-with-vi-c63a4ba9a63823a2PharmaRadar360en2026-09-22T12:30:00.000ZPreliminary data: social anxiety scores improved 31 points in four months with Vistagen’s nasal sprayhttps://www.pharmaradar360.com/article/wisner-baum-investigates-generic-drug-quality-as-2026-patent-cliff-accelerates-c-579b2debb3e49258PharmaRadar360en2026-09-22T12:19:48.000ZWisner Baum Investigates Generic Drug Quality as 2026 Patent Cliff Accelerates Competitionhttps://www.pharmaradar360.com/article/otsuka-announces-transformative-phase-3-fusion-results-for-ulefnersen-bringing-t-d5ff980a261f735cPharmaRadar360en2026-09-22T12:00:00.000ZOtsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatmenthttps://www.pharmaradar360.com/article/claros-technologies-announces-continued-commercial-expansion-into-europe-and-ent-21dc3bd5985bea1bPharmaRadar360en2026-09-22T12:00:00.000ZClaros Technologies Announces Continued Commercial Expansion into Europe and Entry into Pharmaceutical Manufacturing with a Successful PFAS Destruction Pilot at Bachem AGhttps://www.pharmaradar360.com/article/allergan-aesthetics-debuts-aa-signaturetm-in-the-united-states-with-skin360-its-3fb68c46a13552f5PharmaRadar360en2026-09-22T12:00:00.000ZAllergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approachhttps://www.pharmaradar360.com/article/phase-3-depression-data-could-define-the-case-for-cybin-stock-bf3ee7c531131e23PharmaRadar360en2026-09-22T11:25:22.000ZPhase 3 Depression Data Could Define The Case For Cybin Stockhttps://www.pharmaradar360.com/article/newron-presents-h1-2026-results-and-provides-corporate-update-12c4c38dc6d0be1aPharmaRadar360en2026-09-22T11:24:06.000ZNewron presents H1 2026 results and provides corporate updatehttps://www.pharmaradar360.com/article/celldex-reports-positive-phase-3-results-for-barzolvolimab-in-chronic-spontaneou-0017f5ea9d432ed0PharmaRadar360en2026-09-22T11:00:00.000ZCelldex Reports Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticariahttps://www.pharmaradar360.com/article/celldex-announces-positive-results-from-phase-3-embarq-csu1-c8dfd9af985de52bPharmaRadar360en2026-09-22T10:58:00.000ZCelldex Announces Positive Results from Phase 3 EMBARQ-CSU1https://www.pharmaradar360.com/article/bofa-securities-names-top-biotech-stock-amid-sector-rally-65a732f8b3124bfcPharmaRadar360en2026-09-22T10:56:47.000ZBofA Securities Names Top Biotech Stock Amid Sector Rallyhttps://www.pharmaradar360.com/article/a-merck-drug-cut-the-risk-of-worsening-disease-by-76-the-fda-updated-its-label-35639d1ef2653d3ePharmaRadar360en2026-09-22T10:50:31.000ZA Merck drug cut the risk of worsening disease by 76%. The FDA updated its label.https://www.pharmaradar360.com/article/us-phenylephrine-hydrochloride-prices-hold-firm-as-q4-pharmaceutical-demand-stre-0149dcbbdb4b1dc3PharmaRadar360en2026-09-22T10:46:07.000ZUS Phenylephrine Hydrochloride Prices Hold Firm as Q4 Pharmaceutical Demand Strengthenshttps://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-d63bea0d0db63aa3PharmaRadar360en2026-09-22T10:45:00.000ZU.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)https://www.pharmaradar360.com/article/u-s-fda-approves-update-to-the-label-for-winrevairtm-sotatercept-csrk-to-include-e2755dc1ca6275fcPharmaRadar360en2026-09-22T10:45:00.000ZU.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)https://www.pharmaradar360.com/article/clinical-trials-for-medicines-good-clinical-practice-inspections-68a2c21adf64b7b1PharmaRadar360en2026-09-22T10:42:26.000ZClinical trials for medicines: Good clinical practice inspectionshttps://www.pharmaradar360.com/article/the-drugs-and-devices-have-been-on-the-market-for-years-but-fda-ordered-studies-f39731160de90db0PharmaRadar360en2026-09-22T10:37:24.000ZThe Drugs And Devices Have Been On The Market For Years. But FDA-Ordered Studies Still Aren't Done.https://www.pharmaradar360.com/article/nearly-600-fda-postmarket-drug-studies-are-behind-schedule-while-many-of-the-med-f28350f4fcac615bPharmaRadar360en2026-09-22T10:15:09.000ZNearly 600 FDA Postmarket Drug Studies Are Behind Schedule While Many of the Medicines Stay on the Markethttps://www.pharmaradar360.com/article/beyond-admet-ai-for-medicines-safety-survey-a86c0a5b77beeed2PharmaRadar360en2026-09-22T10:00:05.000ZBeyond ADMET: AI for medicines safety - surveyhttps://www.pharmaradar360.com/article/harmoni-gi1-a-phase-iii-trial-featuring-ivonescimab-plus-chemotherapy-compared-t-5397d986a24a195aPharmaRadar360en2026-09-22T10:00:00.000ZHARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMhttps://www.pharmaradar360.com/article/direct-nitrite-analysis-simplifies-tests-of-pharmaceutical-excipients-for-risk-c-4b362d430ed610eaPharmaRadar360en2026-09-22T10:00:00.000ZDirect nitrite analysis simplifies tests of pharmaceutical excipients for risk checkshttps://www.pharmaradar360.com/article/regulatory-round-up-22-september-2026-5ba9abe7a8a91f88PharmaRadar360en2026-09-22T09:23:41.000ZRegulatory round-up: 22 September 2026https://www.pharmaradar360.com/article/mannkind-corporation-mnkd-stock-analysis-exploring-a-127-68-potential-upside-in-88d42183e45cec68PharmaRadar360en2026-09-22T09:21:38.000ZMannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Spacehttps://www.pharmaradar360.com/article/book-review-the-age-of-cures-by-barry-werth-50b9ec628976b5a2PharmaRadar360en2026-09-22T09:00:43.000ZBook Review: ‘The Age of Cures,’ by Barry Werthhttps://www.pharmaradar360.com/article/boryung-signs-277-mil-taxotere-supply-deal-with-china-s-yifan-6f397d63d69e2dafPharmaRadar360en2026-09-22T08:37:41.000ZBoryung signs $277 mil. Taxotere supply deal with China’s Yifanhttps://www.pharmaradar360.com/article/reg-hikma-pharmaceutical-director-pdmr-shareholding-bb695b3e1242f838PharmaRadar360en2026-09-22T08:32:40.000ZREG - Hikma Pharmaceutical - Director/PDMR Shareholdinghttps://www.pharmaradar360.com/article/ukhsa-and-university-of-oxford-scientists-uncover-genetic-changes-in-the-bacteri-619305ae10369373PharmaRadar360en2026-09-22T08:30:02.000ZUKHSA and University of Oxford scientists uncover genetic changes in the bacteria causing severe Kent meningococcal disease outbreakhttps://www.pharmaradar360.com/article/voluntary-scheme-aggregate-net-sales-and-payment-information-august-2026-1002643f3a56701ePharmaRadar360en2026-09-22T08:30:01.000ZVoluntary scheme aggregate net sales and payment information: August 2026https://www.pharmaradar360.com/article/the-health-impacts-from-industrial-sources-of-pfas-a-rapid-review-ed4c661ce7265e41PharmaRadar360en2026-09-22T08:30:01.000ZThe health impacts from industrial sources of PFAS: a rapid reviewhttps://www.pharmaradar360.com/article/per-and-polyfluoroalkyl-substances-pfas-general-information-49da969af76edf3bPharmaRadar360en2026-09-22T08:30:01.000ZPer- and polyfluoroalkyl substances (PFAS): general informationhttps://www.pharmaradar360.com/article/vpag-quarterly-net-sales-and-payment-information-e87d48f3b7220662PharmaRadar360en2026-09-22T08:30:01.000ZVPAG quarterly net sales and payment informationhttps://www.pharmaradar360.com/article/chemical-hazards-compendium-2cf1a7b32dba1e24PharmaRadar360en2026-09-22T08:30:01.000ZChemical hazards compendiumhttps://www.pharmaradar360.com/article/hanyang-precision-chairman-countersues-former-hanmi-pharmaceutical-executives-29f8aa0fd33812f7PharmaRadar360en2026-09-22T08:20:49.000ZHanyang Precision Chairman Countersues Former Hanmi Pharmaceutical Executiveshttps://www.pharmaradar360.com/article/fda-s-2026-single-trial-default-standard-reframes-the-dual-pivotal-debate-for-sp-db564c899dadd3aaPharmaRadar360en2026-09-22T07:55:18.000ZFDA’s 2026 Single-Trial Default Standard Reframes the Dual-Pivotal Debate for Sponsors Still Designing Phase 3https://www.pharmaradar360.com/article/submicron-ir-for-pharmaceutical-research-development-and-quality-f91eaac67fdb6ecbPharmaRadar360en2026-09-22T07:44:00.000ZSubmicron IR for pharmaceutical research, development, and qualityhttps://www.pharmaradar360.com/article/sant-98561788d726bcd6PharmaRadar360en2026-09-22T07:40:28.000ZΕπίσκεψη αντιπροσωπείας της Επιτροπής Δημόσιας Υγείας (SANT) του Ευρωπαϊκού Κοινοβουλίου στον Εθνικό Οργανισμό Φαρμάκων (ΕΟΦ)https://www.pharmaradar360.com/article/greece-to-prioritise-biosimilars-legislation-during-2027-eu-presidency-says-mini-7c952cb632ab6e86PharmaRadar360en2026-09-22T07:33:46.000ZGreece to prioritise biosimilars legislation during 2027 EU presidency, says ministerhttps://www.pharmaradar360.com/article/mayer-brown-represents-underwriters-on-teva-pharmaceutical-s-us-4-9-billion-seni-c8c0fec7c979c997PharmaRadar360en2026-09-22T07:28:01.000ZMayer Brown represents underwriters on Teva Pharmaceutical’s US$4.9 billion senior notes offering.https://www.pharmaradar360.com/article/iambic-maintains-momentum-from-string-of-big-pharma-partnerships-by-aiming-for-i-14246701c70fe37fPharmaRadar360en2026-09-22T07:14:45.000ZIambic maintains momentum from string of Big Pharma partnerships by aiming for IPOhttps://www.pharmaradar360.com/article/trevi-therapeutics-stock-trades-at-usd-14-71-as-biotech-data-matters-663f1d5418a1fc34PharmaRadar360en2026-09-22T07:13:21.000ZTrevi Therapeutics stock trades at USD 14.71 as biotech data mattershttps://www.pharmaradar360.com/article/how-aspen-s-priyen-naidu-drives-a-human-centred-approach-to-technology-f2ab4450d8792b6aPharmaRadar360en2026-09-22T07:10:56.000ZHow Aspen’s Priyen Naidu drives a human-centred approach to technologyhttps://www.pharmaradar360.com/article/bank-of-america-corp-de-invests-38-35-million-in-ultragenyx-pharmaceutical-inc-r-127cbc20e446c4bfPharmaRadar360en2026-09-22T07:10:01.000ZBank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RAREhttps://www.pharmaradar360.com/article/building-on-success-ipsen-receives-two-new-gold-brandon-hall-awards-d9486765e1c17bb8PharmaRadar360en2026-09-22T07:00:00.000ZBuilding on Success: Ipsen Receives Two New Gold Brandon Hall Awardshttps://www.pharmaradar360.com/article/merry-life-biomedical-starts-phase-2-trial-of-tml-6-for-early-alzheimer-s-045429441a897961PharmaRadar360en2026-09-22T06:45:18.000ZMerry Life Biomedical Starts Phase 2 Trial of TML-6 for Early Alzheimer’shttps://www.pharmaradar360.com/article/ec-approves-obicetrapib-as-oral-cetp-inhibitor-for-hypercholesterolemia-ae296af74503e57aPharmaRadar360en2026-09-22T06:40:39.000ZEC Approves Obicetrapib as Oral CETP Inhibitor for Hypercholesterolemiahttps://www.pharmaradar360.com/article/fda-updates-nonclinical-testing-regulations-140133928ca7c94dPharmaRadar360en2026-09-22T06:30:00.000ZFDA Updates Nonclinical Testing Regulationshttps://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411PharmaRadar360en2026-09-22T06:05:05.000ZBeyond clinical endpoints: Rethinking ALS drug development through disease biologyhttps://www.pharmaradar360.com/article/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-tre-cadbbf2157ab9b29PharmaRadar360en2026-09-22T06:00:00.000ZAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritishttps://www.pharmaradar360.com/article/india-s-biotech-self-reliance-moment-102921bdf8bc7232PharmaRadar360en2026-09-22T05:50:11.000ZIndia’s biotech self-reliance momenthttps://www.pharmaradar360.com/article/5-best-glp-1-stocks-for-2026-and-how-to-invest-99408731658b95c2PharmaRadar360en2026-09-22T05:10:00.000Z5 Best GLP-1 Stocks for 2026 and How to Investhttps://www.pharmaradar360.com/article/boryung-scores-277m-anti-cancer-drug-supply-deal-in-china-d65692bc15e5f4fcPharmaRadar360en2026-09-22T05:02:48.000ZBoryung scores $277m anti-cancer drug supply deal in Chinahttps://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-announces-positive-phase-ii-resu-ca3349841e8c60a5PharmaRadar360en2026-09-22T05:00:00.000Z[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesityhttps://www.pharmaradar360.com/article/healthnet-mea-to-commercialise-comide-er-methylphenidate-er-in-uae-under-exclusi-25f7252f14d192bdPharmaRadar360en2026-09-22T05:00:00.000ZHealthNet MEA to Commercialise COMIDE ER® (Methylphenidate ER) in UAE Under Exclusive Agreement with Anxo Pharmaceuticalhttps://www.pharmaradar360.com/article/child-resistant-locking-closures-market-to-2035-pharmaceutical-safety-mandates-d-ee831d2ecb1081b6PharmaRadar360en2026-09-22T04:46:21.000ZChild-Resistant Locking Closures Market To 2035: Pharmaceutical Safety Mandates Drive Growth - News and Statisticshttps://www.pharmaradar360.com/article/india-news-96d7107e3a341182PharmaRadar360en2026-09-22T04:26:23.000ZIndia Newshttps://www.pharmaradar360.com/article/fda-finally-moves-to-comply-with-2022-law-ending-animal-testing-mandate-3c5286ce175b5ebdPharmaRadar360en2026-09-22T04:07:02.000ZFDA finally moves to comply with 2022 law ending animal testing mandatehttps://www.pharmaradar360.com/article/nvidia-qia-backed-iambic-therapeutics-files-for-us-ipo-as-biotech-boom-rolls-on-478bd63e265078d4PharmaRadar360en2026-09-22T03:35:46.000ZNvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls onhttps://www.pharmaradar360.com/article/us-fda-moves-away-from-animal-testing-how-organoids-ai-organs-on-chips-could-imp-8ae12dc92c9fbd34PharmaRadar360en2026-09-22T03:30:00.000ZUS FDA Moves Away From Animal Testing: How Organoids, AI & Organs-On-Chips Could Impact Drug Researchhttps://www.pharmaradar360.com/article/boryung-signs-277-million-taxotere-supply-deal-with-china-s-yifan-pharmaceutical-a71b4ed4f2241099PharmaRadar360en2026-09-22T03:05:00.000ZBoryung Signs $277 Million Taxotere Supply Deal with China's Yifan Pharmaceuticalhttps://www.pharmaradar360.com/article/melbourne-biotech-turns-to-stem-cell-brain-models-in-alzheimer-s-push-7ea3ae37b3c8e127PharmaRadar360en2026-09-22T02:35:55.000ZMelbourne biotech turns to stem cell brain models in Alzheimer's pushhttps://www.pharmaradar360.com/article/editorial-strict-checks-on-drug-supply-chain-9e99b919fddbd074PharmaRadar360en2026-09-22T02:29:02.000ZEditorial: Strict checks on drug supply chainhttps://www.pharmaradar360.com/article/eli-lilly-makes-another-biotech-bet-ahead-of-retatrutide-data-lly-stock-surges-t-f277b743c44c8524PharmaRadar360en2026-09-22T01:59:24.000ZEli Lilly Makes Another Biotech Bet Ahead Of Retatrutide Data – LLY Stock Surges To Highest In Over 2 Monthshttps://www.pharmaradar360.com/article/lilly-s-breast-cancer-combo-wins-approval-2625666fc10dfe92PharmaRadar360en2026-09-22T01:26:22.000ZLilly’s breast cancer combo wins approvalhttps://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-ultragenyx-pha-eb82ae5a7d95e0efPharmaRadar360en2026-09-22T01:26:00.000ZAnalysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)https://www.pharmaradar360.com/article/analysts-offer-insights-on-healthcare-companies-merck-company-mrk-envista-holdin-90aff1940631b27aPharmaRadar360en2026-09-22T01:10:00.000ZAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE)https://www.pharmaradar360.com/article/gc-wellbeing-and-boryung-expand-korea-hospital-use-of-livnec-injection-chosunbiz-f8357be306326357PharmaRadar360en2026-09-22T00:41:00.000ZGC Wellbeing and Boryung expand Korea hospital use of Livnec injection - CHOSUNBIZhttps://www.pharmaradar360.com/article/pfizer-details-phase-3-sleep-apnea-trial-for-ex-metsera-obesity-drug-9b66bc3b08304ba5PharmaRadar360en2026-09-22T00:38:54.000ZPfizer details phase 3 sleep apnea trial for ex-Metsera obesity drughttps://www.pharmaradar360.com/article/what-glp-1-users-should-know-about-the-potential-risk-of-a-rare-type-of-vision-l-d11a80ef91435ad7PharmaRadar360en2026-09-22T00:17:17.000ZWhat GLP-1 users should know about the potential risk of a rare type of vision losshttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-2122447c5946b5e1PharmaRadar360en2026-09-22T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/national-cancer-institute-notice-of-meeting-8918f24bc0866cb9PharmaRadar360en2026-09-22T00:00:00.000ZNational Cancer Institute; Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-e3d513e458366039PharmaRadar360en2026-09-22T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-774090bba85bb2afPharmaRadar360en2026-09-22T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Questionnaire and Data Collection Testing, Evaluation, and Research for the Health Resources and Services Administration, OMB No. 0915-0379-Revisionhttps://www.pharmaradar360.com/article/nonclinical-testing-terminology-5eba25885ce1826aPharmaRadar360en2026-09-22T00:00:00.000ZNonclinical Testing Terminologyhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-to-omb-for-review-and-approv-c3c6da23622a87aePharmaRadar360en2026-09-22T00:00:00.000ZAgency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Generic Information Collection Request for Health Resources and Services Administration Hotlines, Chatlines, and Online Portalshttps://www.pharmaradar360.com/article/submission-for-omb-review-30-day-comment-request-the-impact-and-costs-of-promoti-1981b0d77e209b56PharmaRadar360en2026-09-22T00:00:00.000ZSubmission for OMB review; 30-Day Comment Request; the Impact and Costs of Promoting Objectivity in Research 42 CFR Part 50 Subpart F and Responsible Prospective Contractors 45 CFR Part 94 (Office of the Director)https://www.pharmaradar360.com/article/center-for-scientific-review-amended-notice-of-meeting-ed0ae1132b37b44cPharmaRadar360en2026-09-22T00:00:00.000ZCenter for Scientific Review; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/national-institute-of-environmental-health-sciences-notice-of-meeting-request-fo-9ec32231184cff8dPharmaRadar360en2026-09-22T00:00:00.000ZNational Institute of Environmental Health Sciences; Notice of Meeting; Request for Public Inputhttps://www.pharmaradar360.com/article/properly-fueling-your-child-for-sports-9a38989fbb516ab5PharmaRadar360en2026-09-22T00:00:00.000ZProperly Fueling Your Child for Sportshttps://www.pharmaradar360.com/article/client-side-ephemeral-de-identification-of-protected-health-information-phi-in-m-1723769fa40654cbPharmaRadar360en2026-09-22T00:00:00.000ZClient-Side Ephemeral De-Identification of Protected Health Information (PHI) in Multi-Center Clinical Trial Analysis and Large Language Model Workflows: Validating Zero-Trust Data Sanitization Under HIPAA Safe Harbor Section 164.514(b)https://www.pharmaradar360.com/article/identification-of-ca2-as-a-potential-candidate-gene-involved-in-the-therapeutic-468ef38d57294912PharmaRadar360en2026-09-22T00:00:00.000ZIdentification of CA2 as a potential candidate gene involved in the therapeutic effect of Huatan Huoxue decoction on polycystic ovary syndrome: An integrated study of network pharmacology, Mendelian randomization, and experimental validation